Inhibitors of kinase networks and uses thereof

Patent metadata

Field	Value
Publication number	US-11040973-B2
Application number	US-201816499133-A
Country	US
Kind code	B2
Filing date	Mar 29, 2018
Priority date	Mar 29, 2017
Publication date	Jun 22, 2021
Grant date	Jun 22, 2021

Abstract

The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and/or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.

First claim

The invention claimed is:

1. A compound having a formula of:

2. A pharmaceutical composition comprising:
the compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers; or
nanoparticles of the compound of claim 1 , together with one or more diluents, excipients, or carriers.

3. The compound according to claim 1 , wherein the compound is a histone demethylase inhibitor.

4. The compound according to claim 1 , wherein the compound is a kinase inhibitor.

5. The pharmaceutical composition of claim 2 further comprising a small molecule or biologic conjugate, wherein the conjugate confers cell-type or tissue-type targeting or the conjugate targets a pathway that synergizes the action of the one or more compounds and/or confers aqueous solubility or low clearance.

6. The pharmaceutical composition of claim 2 , further comprising a moiety that aids the degradation of target proteins.

7. The compound of claim 1 formulated into a prodrug moiety,
Wherein the prodrug moiety is selected from the group consisting of biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogues,
wherein the prodrug moiety is configured for removal at a specific location within a subject following administration to the subject.

Assignees

• Purdue Research Foundation

Inventors

• Sintim Herman O
• Dayal Neetu
• Opoku-Temeng Clement

Classifications

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• C07D221/12

  Phenanthridines · CPC title

• C07D491/147

  the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom · CPC title

• C07D471/14 Primary

  Ortho-condensed systems · CPC title

• C07D209/08

  with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring · CPC title